Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?

被引：0
作者：
Jing Xi
Cynthia X. Ma
机构：
[1] Washington University School of Medicine,Section of Medical Oncology, Division of Oncology, Department of Internal Medicine
[2] Washington University School of Medicine,Siteman Cancer Center
来源：
Current Oncology Reports | 2020年 / 22卷
关键词：
Metastatic breast cancer (MBC); Hormone receptor-positive (HR+) and HER2-negative (HER2−) breast cancer; Estrogen receptor-positive (ER+) breast cancer; CDK4/6 inhibitor; Endocrine therapy; Biomarkers; Sequencing of therapy; Resistance mechanisms; Clinical trials; PI3K inhibitor; mTOR inhibitor; FGFR inhibitor; CDK inhibitor; Aurora kinase inhibitor; RB1; PIK3CA; ESR1; Palbociclib; Abemaciclib; Ribociclib; Alpelisib; Everolimus; Selective estrogen receptor downregulator (SERD); Fulvestrant; Aromatase inhibitor; Targeted therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 496 条
[1]  
Siegel RL(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-34
[2]  
Miller KD(2017)Estimation of the number of women living with metastatic breast cancer in the United States Cancer Epidemiol Biomark Prev 26 809-815
[3]  
Jemal A(2009)PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro Breast Cancer Res 11 R77-25
[4]  
Mariotto AB(2017)New insights in estrogen receptor (ER) biology and implications for treatment Current Breast Cancer Reports 9 13-35
[5]  
Finn RS(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 25-1748
[6]  
Oza A(2016)Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer N Engl J Med 375 1738-1547
[7]  
Ma CX(2018)Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Ann Oncol 29 1541-1936
[8]  
Finn RS(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1925-3646
[9]  
Crown JP(2017)MONARCH 3: abemaciclib as initial therapy for advanced breast cancer J Clin Oncol 35 3638-729
[10]  
Lang I(2019)MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer NPJ Breast Cancer 5 5-915
12345678910